CliffBio
biologic

Havrix

Hepatitis A Vaccine

Loss of exclusivityFebruary 2007projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameHavrix
Active ingredientHepatitis A Vaccine
Strength720ELISA U/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 1995
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Havrix patent cliff — loss of exclusivity February 2007 | CliffBio